MNG1209
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.467
- OXIDATIVE_PHOSPHORYLATION+0.279
- PEROXISOME+0.266
- FATTY_ACID_METABOLISM+0.249
- HEME_METABOLISM+0.239
- ADIPOGENESIS+0.230
- ANDROGEN_RESPONSE+0.218
- TGF_BETA_SIGNALING+0.217
- E2F_TARGETS+0.207
- ESTROGEN_RESPONSE_LATE+0.204
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.461
- MYC_TARGETS_V2-0.416
- IL6_JAK_STAT3_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.354
- INFLAMMATORY_RESPONSE-0.328
- MYOGENESIS-0.228
- INTERFERON_GAMMA_RESPONSE-0.225
- IL2_STAT5_SIGNALING-0.210
- TNFA_SIGNALING_VIA_NFKB-0.190
- HYPOXIA-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.855 |
| 2 | MNG1024 | — | — | 0.813 |
| 3 | MNG1070 | — | — | 0.805 |
| 4 | 20120126.LumB | — | B | 0.802 |
| 5 | 32adc071-1061-45e9-9600-256135f594d9 | — | — | 0.796 |
| 6 | SRR1516049 | — | — | 0.784 |
| 7 | MNG1213 | — | — | 0.783 |
| 8 | MNG730 | — | — | 0.777 |
| 9 | MNG1056 | — | — | 0.763 |
| 10 | SRR12202419 | — | — | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.467 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.279 | Remibrutinib | — uncovered |
| PEROXISOME | 0.266 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.249 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.239 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.218 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.217 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.207 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.204 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.154 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.152 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.147 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.135 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.112 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.095 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.091 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.074 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.069 | Inavolisib | — uncovered |